Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fermé, C.
Right arrow Articles by Diviné, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fermé, C.
Right arrow Articles by Diviné, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:96-97, 2002
© 2002 European Society for Medical Oncology

Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences

C. Fermé1, N. Mounier1 and M. Diviné On behalf of the Groupe d'Études des Lymphomes de l'Adulte (GELA)1

1 Service d'Hématologie, Institut Gustave Roussy, Villejuif, France

Abstract

Background: The optimal treatment for patients with advanced Hodgkin's disease (HD) responding to initial chemotherapy (CT) and an intensive salvage therapy for those who fail to respond completely after initial treatment were evaluated prospectively.

Patients and methods: The Groupe d'études des Lymphomes de l'Adulte H89 trial compared two cycles of CT with (sub)total nodal irradiation (RT) as consolidation treatments for patients with stage IIIB/IV HD with a complete response (CR) or good partial response (PR) after six cycles of CT. Early salvage therapy, including intensified cytoreductive CT and high-dose CT with autologous stem-cell transplantation, was integrated into the trial for patients who had failed to respond completely or relapsed after initial treatment.

Results: The study does not demonstrate any advantage of RT over CT as consolidation treatment at the time of CT-induced CR or good PR. Early intensive therapy improves the outcomes of patients with PR and those who relapsed with unfavourable factors. This strategy remains unsatisfactory for patients with primary refractory disease and chemoresistant disease.

Conclusion: Based on first intensification of conventional-dose CT, in the next trial (EORTC–GELA Intergroup Study), four escalated bleomycin–etoposide–doxorubicin–cyclophosphamide–procarbazine–prednisone (BEACOPP) followed by four baseline BEACOPP are compared with the eight doxorubicin–bleomycin–vinblastine–dacarbazine standard with no RT for patients who achieve CR/CR-uncertain after initial CT.

advanced stages; high-dose therapy; Hodgkin's disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.